樂
樂觀
樂觀 · 25%TAK
$18.07
情境價格
$19.670
+0.222 (+1.13%)收盤時
Loading chart…
- 最高
- 19.705
- 開盤
- 19.670
- 成交量加權均價
- 19.65
- 成交量
- 2.83M
- 市值
- 40.51B
- 最低
- 19.561
- 成交金額
- 55.55M
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 3.05
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.
AI 分析 of Takeda Pharmaceutical Co Ltd (TAK)
買進Takeda Pharmaceutical Co Ltd is a good buy right now, with a current price of 19.67 and a strong year-to-date change of +25.93%. The stock has shown resilience with a 5-day change of +5.02%, and the upcoming FDA decision on Zasocitinib could further boost its prospects. However, the main risk lies in its recent earnings volatility, as seen in the last quarter where the EPS was reported at 0.48, exceeding the estimate of 0.41, but still reflecting fluctuations in net income.
估值指標
Takeda Pharmaceutical Co Ltd（TAK）目前預期本益比為 11.47，5 年平均預期本益比為 25.23。
Alphio AI 對 TAK 的價格情境
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。
事件時間軸
資訊
2.010-19NewsfilterENTYVIO Treatment Shows Significant Efficacy in UC Patients
- 5.010-15Newsfilter
ORZEYFUL Approved for Launch in Japan and China
- 9.009-30Newsfilter
Zasocitinib Shows Superiority in Psoriasis Treatment
- 9.009-22Newsfilter
Takeda Unveils New Data at ESMO Congress on Cancer Treatments
- 8.509-18Newsfilter
Takeda Awards $22.2 Million to 2026 Global CSR Partners
TAK 常見問題 —— 由 Alphio AI 解答
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies. It operates in the Healthcare sector.
Takeda Pharmaceutical Co Ltd is a good buy right now, with a current price of 19.67 and a strong year-to-date change of +25.93%. The stock has shown resilience with a 5-day change of +5.02%, and the upcoming FDA decision on Zasocitinib could further boost its prospects. However, the main risk lies in its recent earnings volatility, as seen in the last quarter where the EPS was reported at 0.48, exceeding the estimate of 0.41, but still reflecting fluctuations in net income.
社群
更多 ↗暫無貼文
註冊或登入後參與討論本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。